🚀 VC round data is live in beta, check it out!
Atara Biotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Atara Biotherapeutics and similar public comparables like Radiopharm Theranostics, Jasper Therapeutics, Lisata Therapeutics, Zhengye Biotechnology and more.
Atara Biotherapeutics Overview
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Founded
2012
HQ
Employees
153
Website
Sectors
Financials (LTM)
EV
$42M
Atara Biotherapeutics Financials
Atara Biotherapeutics reported last 12-month revenue of $101M and EBITDA of $29M.
In the same LTM period, Atara Biotherapeutics generated $80M in gross profit, $29M in EBITDA, and $24M in net income.
Revenue (LTM)
Atara Biotherapeutics P&L
In the most recent fiscal year, Atara Biotherapeutics reported revenue of $129M and EBITDA of ($76M).
Atara Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $101M | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $80M | XXX | $108M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $29M | XXX | ($76M) | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | (59%) | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | (65%) | XXX | XXX | XXX |
| Net Profit | $24M | XXX | ($85M) | XXX | XXX | XXX |
| Net Margin | 24% | XXX | (66%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atara Biotherapeutics Stock Performance
Atara Biotherapeutics has current market cap of $38M, and enterprise value of $42M.
Market Cap Evolution
Atara Biotherapeutics' stock price is $5.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42M | $38M | 0.0% | XXX | XXX | XXX | $-11.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtara Biotherapeutics Valuation Multiples
Atara Biotherapeutics trades at 0.4x EV/Revenue multiple, and 1.4x EV/EBITDA.
EV / Revenue (LTM)
Atara Biotherapeutics Financial Valuation Multiples
As of March 18, 2026, Atara Biotherapeutics has market cap of $38M and EV of $42M.
Equity research analysts estimate Atara Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atara Biotherapeutics has a P/E ratio of 1.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $42M | XXX | $42M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 1.4x | XXX | (0.6x) | XXX | XXX | XXX |
| EV/EBIT | 1.5x | XXX | (0.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| P/E | 1.6x | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atara Biotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Atara Biotherapeutics Margins & Growth Rates
Atara Biotherapeutics' revenue in the last 12 month declined by (68%).
Atara Biotherapeutics' revenue per employee in the last FY averaged $0.7M.
Atara Biotherapeutics' rule of 40 is (39%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atara Biotherapeutics' rule of X is (141%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Atara Biotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (68%) | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | (59%) | XXX | XXX | XXX |
| EBITDA Growth | (114%) | XXX | (150%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (39%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (141%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 31% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 30% | XXX | 118% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 148% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Atara Biotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Tvardi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atara Biotherapeutics M&A Activity
Atara Biotherapeutics acquired XXX companies to date.
Last acquisition by Atara Biotherapeutics was on XXXXXXXX, XXXXX. Atara Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Atara Biotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAtara Biotherapeutics Investment Activity
Atara Biotherapeutics invested in XXX companies to date.
Atara Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Atara Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Atara Biotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atara Biotherapeutics
| When was Atara Biotherapeutics founded? | Atara Biotherapeutics was founded in 2012. |
| Where is Atara Biotherapeutics headquartered? | Atara Biotherapeutics is headquartered in United States. |
| How many employees does Atara Biotherapeutics have? | As of today, Atara Biotherapeutics has over 153 employees. |
| Who is the CEO of Atara Biotherapeutics? | Atara Biotherapeutics' CEO is AnhCo Nguyen. |
| Is Atara Biotherapeutics publicly listed? | Yes, Atara Biotherapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Atara Biotherapeutics? | Atara Biotherapeutics trades under ATRA ticker. |
| When did Atara Biotherapeutics go public? | Atara Biotherapeutics went public in 2014. |
| Who are competitors of Atara Biotherapeutics? | Atara Biotherapeutics main competitors are Radiopharm Theranostics, Jasper Therapeutics, Lisata Therapeutics, Zhengye Biotechnology. |
| What is the current market cap of Atara Biotherapeutics? | Atara Biotherapeutics' current market cap is $38M. |
| What is the current revenue of Atara Biotherapeutics? | Atara Biotherapeutics' last 12 months revenue is $101M. |
| What is the current revenue growth of Atara Biotherapeutics? | Atara Biotherapeutics revenue growth (NTM/LTM) is (68%). |
| What is the current EV/Revenue multiple of Atara Biotherapeutics? | Current revenue multiple of Atara Biotherapeutics is 0.4x. |
| Is Atara Biotherapeutics profitable? | Yes, Atara Biotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Atara Biotherapeutics? | Atara Biotherapeutics' last 12 months EBITDA is $29M. |
| What is Atara Biotherapeutics' EBITDA margin? | Atara Biotherapeutics' last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Atara Biotherapeutics? | Current EBITDA multiple of Atara Biotherapeutics is 1.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.